Literature DB >> 10583299

24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.

A Ortiz1, L F Martínez de Haro, P Parrilla, J Molina, J Bermejo, V Munitiz.   

Abstract

BACKGROUND: Control of acid reflux is the main objective of treatment for Barrett's oesophagus. However, as these patients have a reduced sensitivity to acid reflux, disappearance of symptoms may not correlate with efficient control of acid reflux. The aim of this study was to determine in a group of patients with Barrett's oesophagus whether treatment with proton pump inhibitors suppressed pathological acid reflux once the symptoms of reflux had been controlled and the associated inflammatory lesions cured.
METHODS: Eighteen consecutive patients with Barrett's oesophagus were studied, all of whom presented with heartburn. Twenty-four-hour oesophageal pH monitoring before treatment showed pathological acid reflux in all cases: median percentage of total time with pH less than 4, 22 (range 8-52) per cent. All patients received proton pump inhibitors (dose 20-60 mg/day) until symptoms were controlled.
RESULTS: While on therapy, pH was reduced (median percentage of total time with pH less than 4, 3 versus 22 per cent; P < 0.001). However, three patients had persistent pathological rates of acid reflux.
CONCLUSION: Disappearance of symptoms is not a good indicator of control of pathological acid reflux in patients with Barrett's oesophagus. Twenty-four-hour pH monitoring should be performed for proper adjustment of the dose of medication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583299     DOI: 10.1046/j.1365-2168.1999.01273.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Joaquín Molina; Juan Bermejo; Manuel Canteras
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

2.  Proximal and distal esophageal sensitivity is decreased in patients with Barrett's esophagus.

Authors:  Anne L Krarup; Søren S Olesen; Peter Funch-Jensen; Hans Gregersen; Asbjørn M Drewes
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 3.  Ambulatory esophageal pH monitoring: technique, interpretations, and clinical indications.

Authors:  Radha K Dhiman; Vivek A Saraswat; Subhash R Naik
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

4.  Symptoms, acid exposure and motility in patients with Barrett's esophagus.

Authors:  Michael G Brandt; Gail E Darling; Linda Miller
Journal:  Can J Surg       Date:  2004-02       Impact factor: 2.089

5.  Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial.

Authors:  Karim S Trad; William E Barnes; Gilbert Simoni; Ahmad B Shughoury; Peter G Mavrelis; Mamoon Raza; Jeffrey A Heise; Daniel G Turgeon; Mark A Fox
Journal:  Surg Innov       Date:  2014-04-21       Impact factor: 2.058

6.  The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective.

Authors:  Karim S Trad; William E Barnes; Elizabeth R Prevou; Gilbert Simoni; Jennifer A Steffen; Ahmad B Shughoury; Mamoon Raza; Jeffrey A Heise; Mark A Fox; Peter G Mavrelis
Journal:  Surg Innov       Date:  2018-02-06       Impact factor: 2.058

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.